Femasys (NASDAQ:FEMY) Given Buy Rating at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Separately, Jones Trading lowered their price target on Femasys from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th.

Femasys Stock Performance

NASDAQ FEMY opened at $0.98 on Wednesday. The stock has a market capitalization of $25.12 million, a price-to-earnings ratio of -1.08 and a beta of -2.62. Femasys has a twelve month low of $0.69 and a twelve month high of $1.80. The company has a current ratio of 0.93, a quick ratio of 0.54 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average of $1.02 and a 200 day moving average of $1.19.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $1.14 million. Femasys had a negative net margin of 1,242.06% and a negative return on equity of 392.45%. Sell-side analysts anticipate that Femasys will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Femasys

Hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its stake in shares of Femasys by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 216,164 shares of the company’s stock valued at $238,000 after buying an additional 9,681 shares during the period. Clear Creek Financial Management LLC raised its position in shares of Femasys by 5.5% during the 1st quarter. Clear Creek Financial Management LLC now owns 270,371 shares of the company’s stock valued at $338,000 after buying an additional 14,000 shares during the period. Virtu Financial LLC acquired a new position in Femasys in the fourth quarter valued at approximately $25,000. Jane Street Group LLC purchased a new position in Femasys in the fourth quarter worth approximately $30,000. Finally, Northern Trust Corp grew its position in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock worth $139,000 after acquiring an additional 37,675 shares during the period. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.